Search

Your search keyword '"Villar, Luisa M."' showing total 5 results
Start Over Author "Villar, Luisa M." Language spanish; castilian
5 results on '"Villar, Luisa M."'

4. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).

Author

Fernández Ó, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, Comabella M, de las Heras V, García-Merino JA, Hernández-Pérez MA, Izquierdo G, Matas E, Meca-Lallana JE, Mendibe-Bilbao Mdel M, Muñoz-García D, Olascoaga J, Oreja-Guevara C, Prieto JM, Ramió-Torrentà L, Rodríguez-Antigüedad A, Saiz A, Téllez N, Villar LM, and Tintoré M

Subjects
Antibodies, Monoclonal therapeutic use, Clinical Trials as Topic methods, Drug Design, Europe, Humans, Immunotherapy methods, Leukoencephalopathy, Progressive Multifocal chemically induced, Leukoencephalopathy, Progressive Multifocal prevention & control, Mesenchymal Stem Cell Transplantation, Molecular Targeted Therapy, Multiple Sclerosis epidemiology, Multiple Sclerosis immunology, Pharmacovigilance, Therapies, Investigational, Antirheumatic Agents therapeutic use, Multiple Sclerosis drug therapy
Abstract

The most significant data presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in France in October 2012, have been summarised in the fifth edition of the Post-ECTRIMS Experts Meeting, held in Madrid in October 2012. This led to the drafting of this review, which has been published in three parts. This third part of the Post-ECTRIMS review presents the findings from the latest studies conducted with disease-modifying treatments, more specifically with glatiramer acetate, laquinimod, ponesimod, BG-12, teriflunomide, daclizumab, natalizumab and secukinumab (AIN457). Likewise, we also address the reasons that justify the search for innovative treatments for multiple sclerosis, with antigen-specific therapy, cell therapy and therapy aimed at promoting remyelination being highlighted among other future therapeutic strategies. Access to new pharmacological agents and the complexity of the therapy of multiple sclerosis in the future will require new design strategies and directions in clinical trials, including the use of surrogate markers, new statistical applications, superiority, inferiority or equivalence clinical trials and adaptable designs.

Published
2013

5. [Biomarkers in multiple sclerosis].

Author

Fernández Ó, Arroyo-González R, Rodríguez-Antigüedad A, García-Merino JA, Comabella M, Villar LM, Izquierdo G, Tintoré M, Oreja-Guevara C, Álvarez-Cermeño JC, Meca-Lallana JE, Prieto JM, Ramió-Torrentà L, Martínez-Yélamos S, and Montalban X

Subjects
Age of Onset, Biomarkers analysis, Blood Proteins analysis, Body Fluids chemistry, Cerebrospinal Fluid Proteins analysis, Disability Evaluation, Drug Monitoring, Female, Glatiramer Acetate, HLA-D Antigens analysis, Humans, Immunoglobulin Light Chains urine, Inflammation Mediators analysis, Lymphocyte Count, Magnetic Resonance Imaging, Male, Multiple Sclerosis classification, Multiple Sclerosis diagnosis, Multiple Sclerosis drug therapy, Multiple Sclerosis epidemiology, Nerve Tissue Proteins analysis, Oligoclonal Bands analysis, Oligoclonal Bands cerebrospinal fluid, Peptides therapeutic use, Prognosis, Saliva chemistry, Severity of Illness Index, Sex Distribution, T-Lymphocyte Subsets drug effects, Tears chemistry, Tomography, Optical Coherence, Multiple Sclerosis metabolism
Abstract

Multiple sclerosis is the most frequent disabling neurological disease in young adults. Its development includes independent processes of inflammation, demyelination, neurodegeneration, gliosis and repair, which are responsible for the heterogeneity and individual variability in the expression of the disease, its prognosis and response to treatment. As part of personalised medicine, the progress made in the search for new biomarkers has identified promising candidates that may be useful for the early diagnosis of the disease, for detecting prognostic and developmental profiles of the disease, and for monitoring the response to treatment. Unfortunately, few of them have been validated adequately, which prevents them from being applied in clinical practice. In view of the latest findings, the experts recommend orienting research in another direction, not so much towards the discovery of new molecules or imaging techniques, but instead towards a clinical validation of these markers, with the aim of fostering translational research. This review offers an update on the information about the biomarkers in multiple sclerosis that have currently been validated and are thus potential candidates, as well as looking at their value in the diagnosis, prognosis, evaluation of the development of the disability caused by the disease and the response to therapy.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results